Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non–small-cell lung cancer

R Pérez-Soler - Clinical lung cancer, 2004 - Elsevier
Abstract Erlotinib (OSI-774; Tarceva™) is an orally available, highly specific epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with …
被引用次数：110 相关文章

Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer

R Perez-Soler - Clinical lung cancer, 2004 - pubmed.ncbi.nlm.nih.gov
Erlotinib (OSI-774; Tarceva) is an orally available, highly specific epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with erlotinib in …

Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer

R Pérez-Soler - Clinical lung cancer, 2004 - einstein.elsevierpure.com
Abstract Erlotinib (OSI-774; Tarceva™) is an orally available, highly specific epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with …

Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.

R Perez-Soler - Clinical Lung Cancer, 2004 - europepmc.org
Erlotinib (OSI-774; Tarceva) is an orally available, highly specific epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with erlotinib in …

[引用][C] Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer

R PEREZ-SOLER - Clin Lung Cancer, 2004 - cir.nii.ac.jp
Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor
erlotinib (OSI-774) in non-small-cell lung cancer | CiNii Research CiNii 国立情報学研究所 学術 …

Phase II Clinical Trial Data with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer

R Pérez-Soler - Clinical Lung Cancer, 2004 - clinical-lung-cancer.com
Abstract Erlotinib (OSI-774; Tarceva™) is an orally available, highly specific epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with …

Phase II Clinical Trial Data with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer

R Pérez-Soler - Clinical Lung Cancer, 2004 - infona.pl
Erlotinib (OSI-774; Tarceva™) is an orally available, highly specific epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with erlotinib in …